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Background: Aortic infections, even with treatment, have a high mortality and risk of recurrent infection and limb loss.
Cryopreserved aortoiliac allograft (CAA) has been proposed for aortic reconstruction to improve outcomes in this high-
risk population.
Methods: A multicenter study using a standardized database was performed at 14 of the 20 highest volume institutions
that used CAA for aortic reconstruction in the setting of infection or those at high risk for prosthetic graft infection.
Results: Two hundred twenty patients (mean age, 65; male:female, 1.6/1) were treated since 2002 for culture positive
aortic graft infection (60%), culture negative aortic graft infection (16%), enteric ﬁstula/erosion (15%), infected pseu-
doaneurysm adjacent to the aortic graft (4%), and other (4%). Intraop cultures indicated infection in 66%. Distal anas-
tomosis was to the femoral artery and iliac. Mean hospital length of stay was 24 days, and 30-day mortality was 9%.
Complications occurred in 24% and included persistent sepsis (n[ 17), CAA thrombosis (n[ 9), CAA rupture (n[ 8),
recurrent CAA/aortic infection (n [ 8), CAA pseudoaneurysm (n [ 6), recurrence of aortoenteric ﬁstula (n [ 4), and
compartment syndrome (n [ 1). Patients with full graft excision had signiﬁcantly better outcomes. Ten (5%) patients
required allograft explant. Mean follow-up was 30 6 3 months. Freedom from graft-related complications, graft explant,
and limb loss was 80%, 88%, and 97%, respectively, at 5 years. Primary graft patency was 97% at 5 years, and patient
survival was 75% at 1 year and 51% at 5 years.
Conclusions: This largest study of CAA indicates that CAA allows aortic reconstruction in the setting of infection or
those at high risk for infection with lower early and long-term morbidity and mortality than other previously reported
treatment options. Repair with CAA is associated with low rates of aneurysm formation, recurrent infection, aortic
blowout, and limb loss. We believe that CAA should be considered a ﬁrst line treatment of aortic infections. (J Vasc
Surg 2014;59:669-74.)Aortic graft infections are rare, occurring in 0.2%-5% of
open aortic reconstructive cases, and they occur less
frequently with endovascular aortic procedures.1-3 These
infections, when they occur, may lead to graft/arterial inter-
face disruption, recurrent hemorrhage, or sepsis, and are
associated with signiﬁcant morbidity and mortality.4 The
treatment of patients with aortic graft infection is one of
the greatest challenges in vascular surgery, and has led to
many alternative methods of treatment, which are often
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://dx.doi.org/10.1016/j.jvs.2013.09.009anatomic bypass, in-line reconstruction with antibiotic
soaked prosthetic grafts, and a neo-aortoiliac system proce-
dure using femoral vein. These procedures are often associ-
ated with signiﬁcant complications such as recurrent graft
infection, aortic stump blowout, or severe leg edema.5
The use of allografts to provide in-line reconstitution of
aortic graft infection and aortic procedures at high risk for
graft infection has been advocated, due to their resistance
to infection.6-8 In addition, the presence of branch vessels
on cryopreserved aortoiliac allograft (CAA) provides
conduits for complex renal or mesenteric bypass proce-
dures, which may reduce the mortality of these procedures.
However, there are a limited number of small series and
case reports on the use of cryopreserved aortic allografts,
and it is unclear whether allograft vein or artery is the pref-
erable conduit. The purpose of our study was to (1) eval-
uate the safety and efﬁcacy of CAA for in-line aortic
reconstruction in patients at high risk for or with aortic
graft infection, and (2) evaluate the United States’ experi-
ence with CAA for aortic reconstruction using a standard-
ized, multi-institutional database, which provides a large
cohort of patients for analysis.
METHODS
Initial single-institution experience. We developed
a database of demographic, comorbid, preoperative imaging,
operative, pathologic, perioperative, and follow-up outcomes669
Table I. Initial aortic procedure indications
Indication No.
% of
total patients
Abdominal aortic aneurysm 165 75
Suprarenal 6
Infrarenal 159
Occlusive disease 51 23
Aortic 9
Aortic þ iliac(s) 42
Trauma- aorta 2 1
Atheroembolism from aorta 1 .5
Iatrogenic aortic injury 1 .5
Type of procedure
Open reconstruction 209 95
Endovascular 11 5
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struction who underwent in-line aortic reconstruction with
CryoArtery Aortoiliac Arterial Allograft (CryoLife, Inc,
Kennesaw, Ga) at the University of California Los Angeles
(UCLA). The University of California Los Angeles Institu-
tional Review Board approved the database and study
methods.9
Multi-institution database development. Our exist-
ing UCLA database was modiﬁed, based on the input of
the coauthors, to capture additional details regarding prior
aortic operations, organism type and species, and diag-
nostic modalities.
Invitations to participate in a multi-institutional study
were then sent to the institutions and surgeons with the
largest experience with CAA, based on distribution records
maintained by the company that processes the CAA. Those
surgeons and institutions expressing an interest in partici-
pating directly contacted the UCLA study team (14 of
the top 20 users of CAA since its introduction) and were
sent “study packages” that included a literature review,
UCLA’s published experience, a study-speciﬁc proposal
with information needed to aid in institutional review
board approval (often expedited), methods to de-identify
the patients and data prior to sending it to a central server,
and the data collection worksheet. All participants were
assisted in obtaining institutional review board approval
at their institution by members of the UCLA study team,
who also provided collaborative support throughout the
entire study and had regular communication with each
institution and most surgeons. Data sources for collection
were left to the discretion of each institution and included,
but were not limited to medical and hospital records, ofﬁce
charts, institutional research databases, billing records,
public death registries, and verbal follow-up with patients.
Appropriate International Classiﬁcation of Diseases, Ninth
Revision and current procedural terminology codes for
aortic graft infection management were provided to each
institution to assist in ﬁnding patients who were treated
with CAA for aortic graft infection over the study period.
Database management. After appropriate study
approval was obtained at each institution and hospital,
patient data was collected by each surgeon and institution
and transmitted to the study team. Data was stored in
a password-encrypted central database on a UCLA server
and managed by the Division of Vascular Surgery at the
University of California Los Angeles. The study team and
principal investigator reviewed all patient data for accuracy
and completeness as it was received; incomplete entries and
data-entry errors were resolved with each institution’s
principal investigator by the UCLA study team.
Statistics. All data was managed and retained in
a Microsoft Excel (v. 14; Microsoft Corp, Redmond,
Wash) database. Analysis was performed using SPSS Statis-
tics for Mac (v. 20.0; IBM Corporation, Armonk, NY).
Kruskal-Wallis analysis of variance testing and Tukey
b post hoc testing were performed for determination of
operation frequency and outcome independence. Categor-
ical variables are presented by frequency and percent ofstudy population; continuous variables are presented as
mean 6 standard error of mean, unless noted otherwise.
Differences and level of signiﬁcance between groups for
categorical variables were determined using the c2 test or
Fisher exact test. Differences for continuous variables
were analyzed using the independent t-test or Mann-
Whitney U test. Multivariable outcome analysis was per-
formed using binary and multinomial logistic regression
models. Cochran and Mantel-Haenszel methods were
used for hazard ratios (HRs) and 95% conﬁdence intervals
(CIs). Patient survival and freedom from limb loss were
analyzed using Kaplan-Meier Life Table methods. A
P value of <.05 was considered signiﬁcant.RESULTS
Patientswere treated at14of the20highest-volume insti-
tutions from different regions of the United States that use
CAA (Appendix, online only). Two hundred twenty patients
underwent in-line aortic reconstruction with CAAs
(male:female ¼ 1.6/1); mean age was 65 6 standard devia-
tion 12 (range, 31-91 years). Indications for use of CAA
included culture positive aortic graft infection (n ¼ 133;
60%), culture negative aortic graft infection (n ¼ 36; 16%),
graft enteric ﬁstula/erosion (n¼ 33; 15%), infected pseudoa-
neurysm adjacent to the aortic graft (n ¼ 9; 4%), and other
(n¼9;4%), including trauma, increased risk ofgraft infection,
low ﬂow axillo-bifemoral bypass with pelvic ischemia, and
recurrent prosthetic graft thrombosis. Indications and tech-
niques for the initial aortic surgery can be seen in Table I.
One hundred twenty-two of the original grafts were aortic
tube (55%), 66 were bifuricated aortoiliac (30%), and 32
werebifuricated aortofemoral (15%).Themean timebetween
the initial prosthetic aortic graft procedure and CAA implant
was 76 1 months (range, 1-22 months).
Risk factors and comorbidities. Risk factors for
aortic surgery included hypertension (n ¼ 144; 66%),
smoking (n ¼ 118; 54%), diabetes mellitus (n ¼ 55;
25%), immunosuppression (n ¼ 10; 5%), and connective
Table II. Additional procedures performed concomitantly
with cryopreserved aortoiliac allograft (CAA) placement
Procedure No. % of total patients
Femoral-femoral bypass 28 13
Angioplasty 14 6
Thrombectomy 12 5
Femoral-popliteal bypass 10 5
Colon resection 4 2
Femoral-popliteal graft replacement
with cryovein
4 2
Appendectomy 4 2
Duodenal repair 3 1
Iliac endarterectomy 2 1
Femoral endarterectomy 2 1
Other 12 5
Table III. Organisms identiﬁed from intraoperative
cultures of resected prior aortic graft
Organism No.
% of
total patients
Culture negative 75 34
Methicillin-sensitive staphylococcus aureus 21 10
Polymicrobial 21 10
Methicillin-resistant staphylococcus aureus 14 6
Escherichia coli 13 6
Pseudomonas 10 5
Staphylococcus sp 9 4
Enterococcus sp 8 4
Propionibacterium acnes 6 3
Vancomycin resistant enterococcus 6 3
Streptococcus sp 6 3
Salmonella 4 2
Clostridium 4 2
Klebsiella 4 2
Corynebacterium sp 4 2
Bacteroides sp 4 2
Enterobacterium sp 4 2
Other 7 3
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peripheral arterial disease (n ¼ 91; 41%), prior myocardial
infarction (n ¼ 44; 20%), prior stroke (n ¼ 18; 8%), prior
major (n ¼ 14; 6%) and minor amputation (n¼ 6; 3%), and
congestive heart failure (n ¼ 13; 6%).
Operative data. One hundred sixty-three patients
(74%) underwent elective CAA replacement surgery; 57
(26%) were treated emergently with surgery. The mean
American Society of Anesthesiologists score for all patients
was 3.3 6 0.1; the mean for elective cases was 3.0 6 0.1
and 3.4 6 0.1 for emergent cases. The mean length of
operation and estimated blood loss was 464 6 19 minutes
and 2051 6 159 mL, respectively.
Full excision of a prior graft was performed in 149
patients (68%) and partially excised in 71 patients (32%).
The proximal anastomosis was performed to the infrarenal
portion of the aorta in 214 patients (97%), the suprarenal
aorta in four patients (2%), and the supraceliac aorta in
two patients (1%). The distal anastomosis (end-to-end,
n ¼ 160; 73%; end-to-side, n ¼ 60; 27%) was performed
bilaterally to the femoral artery (n ¼ 139; 63%) and iliac
artery (n ¼ 66; 30%), and unilaterally to the femoral
(n ¼ 15; 7%) and iliac artery (n ¼ 15; 7%). Sartorius myo-
plasties were used to cover the femoral artery in 17% (n ¼
37) of reconstructions. Sixty-one patients (27%) required at
least one cryopreserved allograft segment to extend the
graft to the distal anastomotic site. Additional concomitant
vascular procedures included femoral-femoral bypass,
angioplasty, and thrombectomy as shown in Table II;
four of these procedures involved the use of additional cry-
opreserved allograft segments for bypass. The results of
intraoperative cultures are shown in Table III.
Postoperative data and complications. The mean
length of hospital stay was 24 6 2 days; patients were
managed postoperatively with antibiotics for a mean of
48 6 8 days. Patient outcomes were not dependent on
the institutional frequency of the CAA operation per-
formed (P ¼ .722). Procedure-related complications
occurred in 24% of patients and included CAA infection,
CAA rupture, CAA thrombosis/occlusion, CAA stenosis,
CAA pseudoaneurysm formation, aorto-enteric ﬁstula
recurrence, new onset of sepsis, and lower extremity
compartment syndrome (Table IV). Factors associated
with CAA-related complications (31 patients; 14%) were
age >70 (HR, 1.657; 95% CI, 1.286-2.512; P ¼ .003),
peripheral arterial disease (HR, 2.050; 95% CI, 1.094-
4.466; P ¼ .027), and virulent, primarily gram negative,
organisms (HR, 2.423; 95% CI, 1.821-3.096; P ¼ .038).
Two CAA were explanted at 7 and 15 days due to recur-
rent infection, diagnosed by imaging and blood cultures
(Table V). Patients requiring late interventions underwent
successful graft angioplasty (n ¼ 5; 2%) and aortoiliac
thrombectomy (n ¼ 2; 1%).
Follow-up data. The mean length of follow-up was
30 6 3 months (range, 1-160 months). A total of 10 CAA
(5%) required explant during study follow-up (Table V).
Factors associated with CAA explant were age >70
(HR, 1.390; 95% CI, 1.081-5.883; P ¼ .041) and partialaortic graft excision (HR, 3.222; 95% CI, 1.357-29.054;
P ¼ .007). After explant, six patients had an extra-anatomic
bypass, three patients had a neo-aortoiliac system proce-
dure, and one patient died intraoperatively. All but the
intraoperative death survived. Freedom from graft-related
complications was 92% at 1 year and 80% at 5 years
(Fig 1), and freedom from graft explant by Life
Table analysis was 99% at 1 year and 88% at 5 years (Fig 2).
Patient survival by Life Table analysis was 75% at 1 year and
51% at 5 years (Fig 3), and primary graft patency by Life
Table analysis was 98% at 1 year and 97% at 5 years and
freedom from limb loss was 98% at 1 year and 93% at
5 years (Fig 3).
DISCUSSION
This is the largest study of cryopreserved aortoiliac
arterial allografts and represents approximately 25% of all
Table IV. Early and late-term postoperative
complications
Complication No. % of total patients
Persistent sepsis 17 8
CAA thrombosis/occlusion 9 4
CAA rupture 8 4
Recurrent CAA infection 8 4
CAA pseudoaneurysm 6 3
Aorto-enteric ﬁstula recurrence 4 2
Lower extremity compartment
syndrome
1 .5
Colonic perforation 1 .5
Lower limb ischemia 1 .5
CAA, Cryopreserved aortoiliac allograft.
Table V. Indications and duration of cryopreserved
aortoiliac allograft (CAA) implant for patients requiring
CAA explant
Patient Indication Duration of CAA implant
1 CAA infection 73 months
2 CAA infection 51 months
3 CAA aneurysm 40 months
4 CAA stenosis 38 months
5 CAA aneurysm 23 months
6 CAA infection 11 months
7 CAA pseudoaneurysm 10 months
8 CAA pseudoaneurysm 5 months
9 CAA infection 15 days
10 CAA infection 7 days
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availability. The conclusions of this study are that CAA
allows for in-line aortic reconstruction in the presence of
infection, with lower patient morbidity and mortality
than the results of other published treatment options for
which long-term results are available, and CAA is associ-
ated with low rates of aneurysm formation, allograft
rupture, recurrent infection, and limb loss.
The mainstay for treating aortic prosthetic graft infec-
tions, and less frequent endovascular graft infections, has
been extra-anatomic bypass, the neo-aortoiliac system
procedure, and unpreserved allograft; however, each of
these treatments is associated with high morbidity.5,10,11
In one of the largest reported series using graft excision
and extra-anatomic bypass, Reilly et al reported aortic
stump blowout occurring in 25% of patients, amputation
in 16%, and a 1-year survival of 73%.12 Better outcomes
have been associated with in situ replacement, eliminating
the risk of aortic stump blowout, using either antibiotic
soaked prosthetic grafts or a neo-aortoiliac system con-
structed from femoral veins. Bandyk et al showed that
the use of prosthetic grafts resulted in 0% early limb loss
while reports of outcomes with neo-aortoiliac system
showed 6% early limb loss and an 83% 1-year survival.13-15
Our study using CAA showed early limb loss in 0%, com-
parable to the best results of small series with in situalternatives. Our study also showed that outcomes were
signiﬁcantly better in patients who had full graft excision,
compared with patients with partial graft excision, probably
due to residual infection in the remaining prosthetic graft.
One of the primary objectives in saving life and limb
during graft infection management is minimizing the inci-
dence of recurrent infection. The reported incidence of
recurrent infection in large series with graft excision and
extra-anatomic bypass is 20%, neo-aortoiliac system is re-
ported to be 13%, and in situ replacement with prosthetic
grafts ranges from 10% to 15%.5,11-13 These incidences
are higher than the rates reported by one midsized series
with cryopreserved allograft16; in our series only eight
patients (4%) had a recurrent infection. There is often
concern about the virulence of organisms that infect aortic
grafts and whether all aortic graft infections and all organ-
isms are appropriate candidates for inline aortic replace-
ment. In our series, patients with virulent organisms had
signiﬁcantly more allograft-related complications but there
was no correlation between recurrent infection and the
presence of an abscess in the retroperitoneum.
The use of fresh allograft has been discontinued in
most institutions due to concerns regarding the graft’s
propensity to dilate over the long term.17 The application
of current cryopreservation techniques has been shown to
preserve the integrity of the collagen matrix, which is
believed to be responsible for fewer graft-related complica-
tions and higher graft patency rates. The beneﬁt of using
cryopreserved allografts is that they are processed so that
they do not require ABO matching. In addition, CAAs
can be selected to match the normal aorta and its branches
in diameter and anatomy and, therefore, are superior to
allografts constructed on the back table in the operating
room of either cryopreserved vein or femoral artery.
Good outcomes have been reported using cryopreserved
femoral artery or vein for aortic reconstruction; however,
the use of these allografts is time consuming and becomes
even more time consuming and complex with involvement
of the renal or visceral arteries.8,18 One of the most advan-
tageous aspects of using CAA is the inclusion of the
visceral, renal, and hypogastric side branches, allowing for
bypass to vessels to avoid renal, mesenteric, and pelvic
ischemia.
The current limitations to our study are that it did not
compare the use of CAA replacement with other recon-
structive treatment options. However, a multicenter
randomized trial would be difﬁcult to conduct with the
low volume of cases at each institution. The use of CAAs
remains limited in the United States, and despite participa-
tion of 14 of the 20 highest volume institutions, many of
those institutions contributed less than 10 patients; there-
fore, the results are as dependent on an individual
surgeon’s skill and experience as the type of conduit.
CONCLUSIONS
This largest study of CAA indicates that repair with
allograft allows in-line reconstruction in the setting of
aortic graft infection with lower early and long-term
Fig 1. Kaplan-Meier analysis of freedom from cryopreserved aortoiliac allograft (CAA)-related complications.
Fig 2. Kaplan-Meier analysis of patient survival, cryopreserved aortoiliac allograft (CAA) primary patency, and freedom
from limb loss.
Fig 3. Kaplan-Meier analysis of freedom from cryopreserved aortoiliac allograft (CAA) explant.
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shed treatment options for which long-term data is avail-
able. Its use is associated with infrequent postoperative
complications such as rupture, recurrent infection, aneu-
rysm formation, and limb loss, making CAA a preferable
alternative to other extra-anatomic or in situ options.
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The contributing institutions and number of cases
submitted are as follows: Indiana University: 35 patients;
Northwestern: 32 patients; Saint Louis University: 28
patients; University of Florida: 25 patients; Stanford
Hospital: 16 patients; Methodist Hospital: 16 patients;University of California Davis: 15 patients; University of
California Los Angeles: 14 patients; Mayo Clinic: 14
patients; Indiana Ohio Heart: 9 patients; Washington
University: 7 patients; Baylor University: 5 patients; Wil-
liam Beaumont Hospital: 3 patients; Advocate Lutheran
General Hospital: 1 patient.
